Postmenopausal hormone therapy and the risk of venous thromboembolism.
Venous thromboembolism (VTE) is an important determinant of the benefit-to-risk profile of postmenopausal hormone replacement therapy (HRT). Women's health practitioners who prescribe HRT to their patients are often more concerned about the thromboembolic complications than the risk of breast malignancy. This is in contrast to their patients who are eligible and considering commencing hormonal treatment where breast cancer is often the primary concern. This review summarizes the data on the actual HRT-related VTE risk and factors influencing it. It also provides practical guidelines which should support the health professional in ensuring informed choice on HRT for women.
Rachoń
D
D
The Jean Hailes Foundation for Women's Health, Monash Institute of Medical Research, Monash University, Melbourne, Australia.
Teede
H
H
D000367:Age Factors; D015992:Body Mass Index; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000009:adverse effects; D004967:Estrogens / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D020249:Hormone Replacement Therapy / Q000009:adverse effects*; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage / Q000009:adverse effects; D017698:Postmenopause; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D012307:Risk Factors; D054556:Venous Thromboembolism / Q000209:etiology*
D003271:Contraceptive Agents, Female; D004967:Estrogens; D017258:Medroxyprogesterone Acetate